SEPTInvestingStart Free

BIAF 8-K: SEC filing

bioAffinity Technologies

Filed with the SEC on · accession 0001493152-26-050541

BIAF filed a 8-K (current report) with the SEC on Nov 6, 2026. bioAffinity Technologies reported Q3 2026 results, highlighting 100% growth in CyPath Lung test unit sales year-to-date and a 79% increase in testing revenue to approximately $1.1 million, alongside pipeline and patent progress.

Summary of the filing

bioAffinity Technologies reported Q3 2026 results, highlighting 100% growth in CyPath Lung test unit sales year-to-date and a 79% increase in testing revenue to approximately $1.1 million, alongside pipeline and patent progress. The company also disclosed raising $8.0 million in gross proceeds through August and October 2026 offerings.

For details, click here →How to read a 8-K →

Key details

CyPath Lung testing revenue for first nine months of 2026$1.1M
Total revenue for Q3 2026$1.1M
Total revenue for Q3 2025$1.4M
Gross proceeds raised through private placement and registered direct offering$8.0M
IssuerbioAffinity Technologies, Inc.
Distribution partner for government healthcare marketsAvMEDICAL
Collaboration partner for next-generation diagnostic testsPictor, Inc.
Supports and funds longitudinal clinical trialJohn P. Murtha Cancer Center Research Program at Uniformed Services University
President and ceoMaria Zannes
Chief medical officerGordon H. Downie, MD, PhD

✦ Ask GOAX AI about this filing — what it means for BIAF, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for BIAF?

Click here

Frequently asked questions

What did BIAF file with the SEC on Nov 6, 2026?

BIAF filed a 8-K (SEC filing). bioAffinity Technologies reported Q3 2026 results, highlighting 100% growth in CyPath Lung test unit sales year-to-date and a 79% increase in testing revenue to approximately $1.1 million, alongside pipeline and patent progress. The company also disclosed raising $8.0 million in gross proceeds through August and October 2026 offerings.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other BIAF SEC filings

Get alerts when BIAF files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
BIAF overviewBIAF analysisBIAF newsLatest SEC filings